Accelerate Diagnostics Announces Certain Preliminary Fourth Quarter and Full-Year 2024 Results
1. AXDX shows significant progress in WAVE system clinical trials. 2. FDA submission expected after trial enrollment completion, possibly early 2025. 3. 2024 revenue approximately $11.7 million, a slight decrease from last year. 4. Cash reserves decreased to $16.3 million, lower than previous quarters. 5. Contract agreements secured for Pheno system, supporting commercial strategy.